Invention Grant
- Patent Title: Agents enhancing HuR/ELAV protein levels for use in the treatment of BRAF-mutated cancers
-
Application No.: US16493893Application Date: 2018-03-14
-
Publication No.: US10772875B2Publication Date: 2020-09-15
- Inventor: Rastine Mérat
- Applicant: LES HOPITAUX UNIVERSITAIRES DE GENEVE
- Applicant Address: CH Geneva
- Assignee: LES HOPITAUX UNIVERSITAIRES DE GENEVE
- Current Assignee: LES HOPITAUX UNIVERSITAIRES DE GENEVE
- Current Assignee Address: CH Geneva
- Agency: Saliwanchik, Lloyd & Eisenschenk
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@78f0660e
- International Application: PCT/EP2018/056315 WO 20180314
- International Announcement: WO2018/167107 WO 20180920
- Main IPC: A61K31/435
- IPC: A61K31/435 ; A61K33/14 ; A61K31/437 ; A61P35/00 ; A61K33/00 ; G01N33/50 ; A61K31/4439 ; A61K31/506
Abstract:
The present invention relates to agents enhancing HuR/ELAV levels for use in the treatment of BRAF-mutated cancers and uses thereof. In particular, the invention relates to the use of agents enhancing HuR/ELAV levels in combination with BRAF inhibitors for the treatment of BRAF-mutated cancers, in particular melanoma and to methods for identifying agents useful for potentiating the effects of BRAF inhibitors, when used in combination.
Public/Granted literature
- US20200085799A1 AGENTS ENHANCING HuR/ELAV PROTEIN LEVELS FOR USE IN THE TREATMENT OF BRAF-MUTATED CANCERS Public/Granted day:2020-03-19
Information query
